Literature DB >> 21044902

A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.

Celia L Gregson1, Peter Hollingworth, Martin Williams, Kirsten A Petrie, Alex N Bullock, Matthew A Brown, Jon H Tobias, James T Triffitt.   

Abstract

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, autosomal dominant condition, classically characterised by heterotopic ossification beginning in childhood and congenital great toe malformations; occurring in response to a c.617 G > A ACVR1 mutation in the functionally important glycine/serine-rich domain of exon 6. Here we describe a novel c.587 T > C mutation in the glycine/serine-rich domain of ACVR1, associated with delayed onset of heterotopic ossification and an exceptionally mild clinical course. Absence of great toe malformations, the presence of early ossification of the cervical spine facets joints, plus mild bilateral camptodactyly of the 5th fingers, together with a novel ACVR1 mutation, are consistent with the 'FOP-variant' syndrome. The c.587 T > C mutation replaces a conserved leucine with proline at residue 196. Modelling of the mutant protein reveals a steric clash with the kinase domain that will weaken interactions with FKBP12 and induce exposure of the glycine/serine-rich repeat. The mutant receptor is predicted to be hypersensitive to ligand stimulation rather than being constitutively active, consistent with the mild clinical phenotype. This case extends our understanding of the 'FOP-variant' syndrome. Crown
Copyright © 2010. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044902      PMCID: PMC3160462          DOI: 10.1016/j.bone.2010.10.164

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  23 in total

1.  Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP).

Authors:  Jennifer L Fiori; Paul C Billings; Lourdes Serrano de la Peña; Frederick S Kaplan; Eileen M Shore
Journal:  J Bone Miner Res       Date:  2006-06       Impact factor: 6.741

2.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

3.  Mechanism of TGFbeta receptor inhibition by FKBP12.

Authors:  Y G Chen; F Liu; J Massague
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

4.  The ACVR1 617G>A mutation is also recurrent in three Japanese patients with fibrodysplasia ossificans progressiva.

Authors:  Masahiro Nakajima; Nobuhiko Haga; Kazuharu Takikawa; Noriyo Manabe; Gen Nishimura; Shiro Ikegawa
Journal:  J Hum Genet       Date:  2007-03-10       Impact factor: 3.172

5.  De novo 617G-A nucleotide mutation in the ACVR1 gene in a Taiwanese patient with fibrodysplasia ossificans progressiva.

Authors:  Gau-Tyan Lin; Hsueh-Wei Chang; Chih-Shan Liu; Peng-Ju Huang; Hsien-Chung Wang; Yuh-Min Cheng
Journal:  J Hum Genet       Date:  2006-11-01       Impact factor: 3.172

6.  A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H).

Authors:  Hirokazu Furuya; Koji Ikezoe; Lixiang Wang; Yasumasa Ohyagi; Kyoko Motomura; Naoki Fujii; Jun-Ichi Kira; Yasuyuki Fukumaki
Journal:  Am J Med Genet A       Date:  2008-02-15       Impact factor: 2.802

7.  Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.

Authors:  Frederick S Kaplan; Meiqi Xu; Petra Seemann; J Michael Connor; David L Glaser; Liam Carroll; Patricia Delai; Elisabeth Fastnacht-Urban; Stephen J Forman; Gabriele Gillessen-Kaesbach; Julie Hoover-Fong; Bernhard Köster; Richard M Pauli; William Reardon; Syed-Adeel Zaidi; Michael Zasloff; Rolf Morhart; Stefan Mundlos; Jay Groppe; Eileen M Shore
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

Review 8.  Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP).

Authors:  Eileen M Shore; Frederick S Kaplan
Journal:  Bone       Date:  2008-05-28       Impact factor: 4.398

9.  FKBP-12 recognition is dispensable for signal generation by type I transforming growth factor-beta receptors.

Authors:  M J Charng; P Kinnunen; J Hawker; T Brand; M D Schneider
Journal:  J Biol Chem       Date:  1996-09-20       Impact factor: 5.157

10.  Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements.

Authors:  Renata Bocciardi; Domenico Bordo; Marco Di Duca; Maja Di Rocco; Roberto Ravazzolo
Journal:  Eur J Hum Genet       Date:  2008-10-01       Impact factor: 4.246

View more
  24 in total

1.  Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.

Authors:  Harry J Han; Payal Jain; Adam C Resnick
Journal:  Bone       Date:  2017-08-02       Impact factor: 4.398

Review 2.  Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation.

Authors:  Irina Hüning; Gabriele Gillessen-Kaesbach
Journal:  Mol Syndromol       Date:  2014-08-07

Review 3.  Molecular and cellular mechanisms of heterotopic ossification.

Authors:  Diana M Ramirez; Melissa R Ramirez; Anthony M Reginato; Damian Medici
Journal:  Histol Histopathol       Date:  2014-05-05       Impact factor: 2.303

Review 4.  Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons.

Authors:  Robert J Pignolo; Eileen M Shore; Frederick S Kaplan
Journal:  Pediatr Endocrinol Rev       Date:  2013-06

5.  Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).

Authors:  Bernard J Smilde; Clemens Stockklausner; Richard Keen; Andrew Whittaker; Alex N Bullock; Annette von Delft; Natasja M van Schoor; Paul B Yu; E Marelise W Eekhoff
Journal:  BMC Musculoskelet Disord       Date:  2022-06-01       Impact factor: 2.562

Review 6.  Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

Authors:  Maurizio Pacifici; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

7.  Analysis of clinical manifestations and treatment in 26 children with fibrodysplasia ossificans progressiva in China.

Authors:  Jun-Mei Zhang; Cai-Feng Li; Shuang-Ying Ke; Yu-Rong Piao; Tong-Xin Han; Wei-Ying Kuang; Jiang Wang; Jiang-Hong Deng; Xiao-Hua Tan; Chao Li
Journal:  World J Pediatr       Date:  2019-09-16       Impact factor: 2.764

8.  Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Authors:  Apirat Chaikuad; Ivan Alfano; Georgina Kerr; Caroline E Sanvitale; Jan H Boergermann; James T Triffitt; Frank von Delft; Stefan Knapp; Petra Knaus; Alex N Bullock
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

9.  From mysteries to medicines: drug development for fibrodysplasia ossificans progressive.

Authors:  Frederick S Kaplan; Robert J Pignolo; Eileen M Shore
Journal:  Expert Opin Orphan Drugs       Date:  2013-08       Impact factor: 0.694

Review 10.  Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis.

Authors:  Frederick S Kaplan; Salin A Chakkalakal; Eileen M Shore
Journal:  Dis Model Mech       Date:  2012-11       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.